Biocon

Our pioneering spirit paved the way for biotechnology in India, and we continue to apply the same spirit in finding novel approaches to improve patient outcomes today for a better tomorrow. This drives us to continuously find new ways to treat diabetes, cancer and autoimmune diseases. Our R&D focuses on prevention, alleviation and treatment and our medicines improve the lives of millions of patients in over 120 countries, by giving them access to life-saving therapies and relief.

What we do

We aim to achieve health equity.

Powered by advanced therapy platforms, our 13,500+ employees blend heart, science and creativity to make better healthcare solutions.

Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation. We have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality. By making medicines more easily accessible for patients across the globe, we’re working towards achieving health equity.